Seeking Alpha

BioCryst advances two new plasma kallikrein inhibitors in quest for HAE prophylactic

BioCryst (BCRX) continues to work towards finding novel treatment options for HAE, as the company advances two optimized plasma kallikrein inhibitors into preclinicals.

The two candidates improved selectivity and bioavailability compared to BCX-4161 with "no effect on prothrombin time at high concentrations." (PR)

BCRX +7.5% premarket

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs